LGND - Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.
NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a $15 million payment from Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) pursuant to the previously disclosed Revenue Participation Right Purchase and Sale Agreement (the “Royalty Purchase Agreement”). The payment completes a scheduled tranche under the agreement and reflects Ligand's continued strategic capital support of Orchestra BioMed's late-stage cardiovascular programs, AVIM Therapy and Virtue SAB, which are both being evaluated in ongoing randomized, controlled pivotal trials.
JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C.
BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.
Ligand Pharmaceuticals (NASDAQ: LGND) detailed plans to acquire XOMA Royalty Corporation in an investor call, outlining what executives described as a "highly complementary" transaction intended to expand Ligand's royalty portfolio and accelerate growth. Under the definitive agreement, Ligand will pay $39 per share in cash to XOMA Royalty shareholders, with a contingent value right (CVR) tied
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of XOMA Royalty Corporation (NasdaqGM: XOMA) to Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). Under the terms of the proposed transaction, shareholders of XOMA will receive $39.00 in cash for each share of XOMA that they own. KSF is seeking to determine whether this consideration and the process.
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the proposed acquisition of the company by Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Stockholders will receive $39.00 and one contingent value right for each share of XOMA Royalty stock that they hold.
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Monday said it is expanding its royalty portfolio through the acquisition of XOMA Royalty Corporation (NASDAQ:XOMA).
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday.
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.50 1 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 2027 2 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla.
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.50 1 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 2027 2 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla.
Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.
B. Metzler seel. Sohn and Co. AG purchased a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 6,879 shares of the biotechnology company's stock, valued at approximately $1,301,000. Other
JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026.
PARIS, France – 22 April 2026: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deliver two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting being held 3-7 May 2026 in Denver, Colorado, as well as a company presentation at Eyecelerator @ ARVO on 1 May 2026.
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.
Olema Pharmaceuticals (NASDAQ: OLMA - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership. Earnings and Valuation This table compares Olema Pharmaceuticals
Aberdeen Group plc cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 37.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 119,309 shares of the biotechnology company's stock after selling 70,439 shares during the period. Aberdeen Group plc